JJ Seeks US Approval for Caplyta in Bipolar Mania
Johnson and Johnson reports its drug Caplyta successfully eased manic symptoms in a second late stage study. The positive results support a planned US regulatory filing seeking approval for bipolar mania.
Xurve View
Insights:
Xurve View
Johnson & Johnson reported that Caplyta eased manic symptoms better than placebo in a second late-stage study, paving the way for a United States regulatory filing. The trial tested a 42 mg daily dose over three weeks in adults with bipolar I disorder. The results strengthen the drug's commercial outlook as the health care giant expands its neuroscience portfolio.
